Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1/2 7Phase 1 4Phase 3 3Phase NA 2

Status

Completed 84Recruiting 35Terminated 22Active not recruiting 12Unknown 11Withdrawn 4Not yet recruiting 2Suspended 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 2Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 35Cisplatin 24fludarabine 23Radiotherapy 23Paclitaxel 21Carboplatin 20pembrolizumab 18Nivolumab 18Magnetic Resonance Spectroscopy 18Specimen Handling 17fludarabine phosphate 15Gemcitabine 15Biopsy 15Cytarabine 14Radiation 11Filgrastim 11Doxorubicin 11Docetaxel 11Dexamethasone 11Radiosurgery 10Granulocyte Colony-Stimulating Factor 10Etoposide 10Melphalan 9Ipilimumab 9venetoclax 8Rituximab 8Calcium Dobesilate 8trametinib 7ibrutinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Cetuximab × Clear all
NCT02630420 2017-10-26

Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer

Yale University

Phase 1 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT02573220 2016-12-09

Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer

University of Chicago

Phase 1 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT01031212 2013-05-13

ASA404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Treating Patients With Refractory Solid Tumors

University of California, San Francisco

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡